Theriva Biologics, Inc.
Close on Oct 19, 2026
- Market cap
- $9.39M
- P/E (TTM)
- –
- Dividend yield
- –
About Theriva Biologics
Pharmaceutical Preparations, SIC 2834
Theriva Biologics, S.L. (operating as an oncology-focused biopharmaceutical business) develops clinical-stage therapeutics to treat solid tumors and related conditions with high unmet medical need. The business concentrates on an oncolytic adenovirus platform engineered to induce tumor cell death, break down tumor stroma via the expression of PH20 hyaluronidase, and stimulate anti-tumor immune responses. Its lead clinical candidate, VCN-01, undergoes evaluation for indications including unresectable metastatic pancreatic ductal adenocarcinoma, pediatric retinoblastoma, and head and neck squamous cell carcinoma, administered either alone or alongside standard-of-care chemotherapy and immunotherapy regimens. The enterprise previously advanced gastrointestinal programs, including SYN-004 and the licensed asset SYN-020.
The business conducts its clinical operations across medical centers and trial sites located in the United States and Europe, specifically maintaining clinical activity in Spain. The provided text outlines clinical development across these regions but does not identify the location of corporate headquarters.
Summary of the business section of Theriva Biologics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Theriva Biologics, Inc.
- Headquarters
- Rockville, MD
- Address
- 9605 Medical Center Drive, Suite 270 20850
- Phone
- (734) 332-7800
- Employees
- 16, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C, Raleigh, North Carolina
Stock & identifiers
- Ticker
- TOVX
- Exchange
- NYSE
- IPO date
- Dec 18, 2006
- Shares outstanding
- 46M, Aug 7, 2026
- Public float
- $3.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Aug 26, 2024; 1-for-25 reverse, Aug 26, 2024; 1-for-10 reverse, Jul 25, 2022; 1-for-10 reverse, Jul 11, 2022; 1-for-35 reverse, Nov 8, 2018; 1-for-35 reverse, Aug 13, 2018; 1-for-3 reverse, Apr 25, 2007
- SEC CIK
- 894158
- CUSIP
- 87164U508
- ISIN
- US87164U5083
- LEI
- 529900RVC1I52VWB3G55
- EIN
- 13-3808303
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven A. Shallcross | CEO and CFO, Director | 250,000 |
| Jeffrey J. Kraws | Director | 228,773 |
| Jeffrey Alan Wolf | Director | 10,842 |
| John J. Monahan | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Steven A. Shallcross | $903.01K | $714.67K | – | $2 | – |
| FY2024 Steven A. Shallcross | $876.31K | $660.27K | – | $15 | – |
| FY2023 Steven A. Shallcross | $1.27M | $1.20M | $379.43K | $95 | – |
| FY2022 Steven A. Shallcross | $1.19M | -$904.22K | $441.26K | $17 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 12, 2026, we employed 16 individuals, all but one of whom are full-time employees.”
Corporate history
Events identified from SEC filings